Back to search

Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets

By Philip M. Parker,  Marion Pierfitte
Published 25 Jan 2016
Reference 6165
Topic Entrepreneurship
Industry Farming
Region Other Regions
Length 3 page(s)
Language English
Inspection copy
Teaching note
6.00
Add to cart
Summary

This case explores the difficulties involved in commercialising vaccines in low-income settings. The focus is the dengue vaccine, launched at the end of 2015, which was first commercialised in emerging markets. It considers issues of affordability and distribution, highlighting the need for business model innovation in all industries.

Teaching objectives

- Identify key decision makers in a market with multiple stakeholders - Understand the need to focus on demand (rather than cost-cutting alone) when supplying the BOP - Exploring the pros and cons of extra-industry and public-private partnerships

Keywords
  • Vaccines
  • Business Model Innovation
  • Dengue
  • Drug delivery
  • Bottom of the pyramid
  • Intrapreneurship
  • Pharmaceuticals
  • Emerging Markets
  • Q21516
  • HMI
  • Pharmaceutical and Medical Device Sectors
Related case to use with this case

Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery

By  Philip M. Parker,  Marion Pierfitte

    Add to cart
    About the authors
    Parker

    Philip M. Parker

    Professor of Marketing

    Marion Pierfitte


    Recommended Cases

    Disrupting Dengue with an Emerging Markets Launch Strategy

    By  Stephen E. Chick,  Ridhima Aggarwal
    Add to cart popular
    Sanofi Pasteur’s newly approved dengue vaccine, Dengvaxia, was unusual in that it was launched in the Philippines and other at-risk countries. By choosing to “flip the model” – launch in an emerging market setting as opposed to developed markets – it had to overcome various obstacles across the value chain, from registration to financing to supply.
      View case

      Should Kazuria Produce Vaccines Locally with Unizima’s Support? Vaccine Manufacturing Capacity in Africa

      By  Stephen E. Chick,  Luk Van Wassenhove,  Prashant Yadav,  Abed Kayyal
      Add to cart new
      New technological developments in biotechnology are creating new opportunities for less centralized production and distribution of biological medicines, including vaccines. This case explores how innovative small-scale production technologies in biotech enable more flexible production of vaccines and other biologic medicines in low- or middle-income countries (LMICs) and neighboring countries.
        View case

        Gardasil Launch

        By  Reinhard Angelmar,  Juliana Kim,  Michael Schroeder
        Add to cart
        Merck & Co is preparing the launch of Gardasil, the first human papillomavirus (HPV) vaccine. Because knowledge of HPV is poor among potential vaccinees and other stakeholders (parents, physicians, third-party payers), and there is no habit of vaccinating adolescents, Merck needs to develop pre-launch programmes.
          View case